Compare Neurocrine Biosciences Inc (NBIX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Southern Copper Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B), while Southern Copper Corp trades at $209.5 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 11.7× Neurocrine Biosciences Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SCCO | |
|---|---|---|
Market Cap | $14.36B | $167.74B |
Volume | 1,237,180 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $219.70 |
52-Week Low | $123.10 | $120.02 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $14.37B | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.
SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
